SAFIR-ABC10 Trial: Precision Medicine Approach Aims to Extend Survival in Bile Duct Cancer
• The SAFIR-ABC10 trial is a precision medicine study offering tailored therapies based on the genetic profile of bile duct tumors.
• The trial includes patients with intrahepatic, perihilar, or distal cholangiocarcinoma, as well as gallbladder cancer.
• The study aims to recruit 800 participants globally, offering one or more of seven anti-cancer therapies matched to tumor targets.
• Early results show promise, with some patients experiencing remission or conversion to operable status, potentially improving survival rates.
© Copyright 2025. All Rights Reserved by MedPath